CONCA, VERONICA
 Distribuzione geografica
Continente #
NA - Nord America 506
EU - Europa 409
AS - Asia 277
AF - Africa 46
OC - Oceania 1
Totale 1.239
Nazione #
US - Stati Uniti d'America 500
IT - Italia 262
CN - Cina 124
SG - Singapore 122
SE - Svezia 52
CI - Costa d'Avorio 34
DE - Germania 24
GB - Regno Unito 14
BG - Bulgaria 13
PL - Polonia 12
HK - Hong Kong 11
FI - Finlandia 9
KR - Corea 7
AT - Austria 6
CA - Canada 6
SN - Senegal 6
NG - Nigeria 5
TR - Turchia 5
FR - Francia 4
IN - India 4
RU - Federazione Russa 4
LT - Lituania 3
NL - Olanda 3
AU - Australia 1
CH - Svizzera 1
EG - Egitto 1
ES - Italia 1
IE - Irlanda 1
IL - Israele 1
JP - Giappone 1
KH - Cambogia 1
PS - Palestinian Territory 1
Totale 1.239
Città #
Santa Clara 142
Chandler 74
Shanghai 67
Singapore 51
Florence 41
Abidjan 34
New York 34
Boardman 33
Pisa 26
Genoa 18
Los Angeles 16
Fairfield 15
Ashburn 14
Cascina 14
Rome 14
Lawrence 13
Princeton 13
Sofia 13
Milan 12
Warsaw 12
London 11
Ogden 11
Bremen 10
Medford 10
Naples 10
Fuzhou 8
Turin 8
Gargallo 7
Hong Kong 7
Dakar 6
Helsinki 6
Munich 6
Wilmington 6
Istanbul 5
Lagos 5
Quanzhou 5
Vienna 5
Kent 4
Ottawa 4
Pistoia 4
San Diego 4
Seoul 4
Verona 4
Adria 3
Ann Arbor 3
Clifton 3
Coreglia Antelminelli 3
Houston 3
Nam-gu 3
Qingdao 3
Anzio 2
Buti 2
Carini 2
Center 2
Civitanova Marche 2
Cologno Monzese 2
Hyderabad 2
Lappeenranta 2
Leverkusen 2
Maiolati Spontini 2
Noventa di Piave 2
Osimo 2
Padova 2
Peccioli 2
Perugia 2
Salerno 2
San Giuliano Terme 2
San Miniato Basso 2
Tempe 2
Toronto 2
Vitry-sur-seine 2
Washington 2
Woodbridge 2
Wuhan 2
Xiamen 2
Bari 1
Benxi 1
Berlingo 1
Billings 1
Buffalo 1
Cairo 1
Castellana Grotte 1
Castiglione Chiavarese 1
Catania 1
Central 1
Città della Pieve 1
Dallas 1
Deiva Marina 1
Dublin 1
Edinburgh 1
Frankfurt am Main 1
Guangzhou 1
Indore 1
Jinan 1
Kowloon 1
Laojunmiao 1
Longhena 1
Melbourne 1
Minervino Murge 1
Nuremberg 1
Totale 902
Nome #
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 76
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 76
null 65
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 63
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 60
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 60
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 60
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 58
null 57
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 55
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development 53
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers 50
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 50
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 43
null 43
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 42
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 40
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 36
null 35
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 35
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 32
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 32
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis 29
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 23
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 21
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 20
Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials 17
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 16
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study 15
null 15
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 14
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 14
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 3
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer 3
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 3
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden 3
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study 2
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 2
Totale 1.321
Categoria #
all - tutte 7.317
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.317


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 10 1 12 10 1 7 13 5 18 34
2022/2023319 23 45 19 19 29 37 10 18 79 1 33 6
2023/2024409 16 29 53 41 30 48 54 13 17 25 44 39
2024/2025482 59 41 19 62 108 140 53 0 0 0 0 0
Totale 1.321